NCT06545890 Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries
| NCT ID | NCT06545890 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Cairo University |
| Condition | Emergence Delirium |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2024-08-10 |
| Primary Completion | 2024-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 46 participants in total. It began in 2024-08-10 with a primary completion date of 2024-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to compare the effectiveness of ketofol for the prevention of emergence delirium in pediatric patients undergoing squint surgery, in comparison to dexmedetomidine.
Eligibility Criteria
Inclusion Criteria: * • All pediatric patients aged 2 to 6 years. * Both sexes. * ASA physical status I and II. * Patients undergoing squint surgery. Exclusion Criteria: * • Refusal of parents. * Patient sensitivity to any of the study medications. * Known neurological disease that can affect the assessment of ED postoperatively.
Contact & Investigator
Karim K Fahim
STUDY DIRECTOR
Professor of Anesthesia, Pain management and Surgical ICU Faculty of Medicine, Cairo University.
Frequently Asked Questions
Who can join the NCT06545890 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 6 Years, studying Emergence Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06545890 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06545890 currently recruiting?
Yes, NCT06545890 is actively recruiting participants. Contact the research team at dr.mki26413@gmail.com for enrollment information.
Where is the NCT06545890 trial being conducted?
This trial is being conducted at Cairo, Egypt, Cairo, Egypt.
Who is sponsoring the NCT06545890 clinical trial?
NCT06545890 is sponsored by Cairo University. The principal investigator is Karim K Fahim at Professor of Anesthesia, Pain management and Surgical ICU Faculty of Medicine, Cairo University.. The trial plans to enroll 46 participants.